- Details
- Hits: 1870
DOPE DISASTER: Legalising cannabis in the UK would fuel violent crime and turn a new generation into hard drug addicts, warn experts - LEGALISING cannabis will fuel violent conflict in our towns and turn a new generation of people on to hard drugs, experts warn. British drug counsellor Seven Graham has seen the damage that easily available cannabis can cause after moving to Los Angeles, where recreational marijuana sale is legal.
Seven tells The Sun on Sunday: “If you think knife crime is bad now, it could get worse if marijuana is legalised. “Legal cannabis does not get rid of the dealers, it normalises drug use and makes the problem worse. “In America, the black market in weed has boomed…
“Legalisation has done nothing to solve gang violence. You would have to be mad to legalise cannabis in Britain.”
Yet hard drug use rocketed in Holland after marijuana was decriminalised.
Former Met detective chief inspector Mick Neville says: “Cannabis is a gateway drug, and letting shops sell it will tempt more people to smoke it…Some will get addicted and move on to other substances. Others will go straight to hard drugs because cannabis is legal and no longer ‘cool’.
- Details
- Hits: 1724
Conclusions: Results of this study show that the frequency with which women in California use cannabis in the year before and during pregnancy has increased over time, corresponding with increasing acceptance of cannabis use and decreasing perceptions of cannabis-associated harms. Future studies are critically needed to determine whether and how the adverse outcomes of maternal perinatal cannabis use on the health and development of infants and children vary with daily vs less frequent use. (July 2019)
Academic review-commentary posted 21/7/19
Unrolling and Unravelling Far-Reaching Implications of Cannabis Use in Pregnancy Study
Albert Stuart Reece, MBBS, FRCS(Ed.), MD | University of Western Australia and Edith Cowan University
The recent paper by Young-Wolff and colleagues reports several major findings relating to cannabis use in pregnancy 1. The data are particularly noteworthy as they were compiled in the northern counties of California which is known to be one of the highest areas of cannabis use in the nation, and has also been identified as a hotspot of both autism and gastroschisis 2. Amongst the authors’ major findings are a marked rise in high intensity use of daily use both before and during pregnancy; the striking differentials in cannabis use by age group, race and income which are seven-fold, twenty-fold and four-fold respectively; and the rate of self-admitted cannabis use in pregnancy reaching almost 4% in 2017, a finding particularly notable in terms of these authors’ prior report that 80% of patients falsely under-report cannabis use 3.Together these data indicate that cannabis is used differentially and disproportionately by the young, the poor and racial minorities – the same epidemiological profile as gastroschisis, an anomaly which has been uniformly linked with cannabis use in all seven studies on this issue 4. Indeed, a recent CDC paper documented a threefold increase in gastroschisis in minority teenage mothers a disparity which quickly collapsed with increasing age 5, just as the pregnancy-cannabis use data of Young-Wolff does. Such data leave open the possibility that small groups of high intensity cannabis users might be contributing disproportionately to adverse neurodevelopmental neonatal and other paediatric outcomes; and suggest that integral-cumulative exposure and intensity of exposure may be paramount. Indeed, cannabis was recently linked with autism rates across US states and shown to be significantly higher under cannabis-liberal regimes 6,7.Nor is it just neurodevelopmental outcomes which are at risk. Cardiovascular defects have also been implicated 8 with atrial septal defect rising substantially in Colorado, Hawaii, Kentucky, Canada and Queensland in association with cannabis 4,9 which further implies that our list of cannabis-related sequalae remains incomplete.Interestingly several national surveys show that the historically low rate of cannabis use amongst African-Americans has risen in recent years. Cannabis acts epigenomically and heritably by altering DNA methylation, histone modification and reduction in total histones 10. Most importantly as agreed by both authors 1,11 the situation is readily amenable to education both of our patients and the public in general, and, since cannabis use in pregnancy closely parallels that in the general community, carry wider implications for cannabis legalization worldwide.
- Details
- Hits: 1731
Ten Cannabis Induced Psychotic Violence by Men Against Women
Cannabis users – ‘Justice’ or ‘Just US?”
- Details
- Hits: 1997
F.D.A. WARNING LETTER Challenging ‘Health Claims of CBD’
Curaleaf, Inc
MARCS-CMS 579289 — JUL 22, 2019
This letter is to advise you that the U.S. Food and Drug Administration (FDA) reviewed your website at the Internet address https://curaleafhemp.com External Link Disclaimer in April and June 2019 and has determined that you take orders there for the products “CBD Lotion,” “CBD Pain-Relief Patch,” “CBD Tincture” (5 versions), “CBD Disposable Vape Pen” (5 versions) and “Bido CBD for Pets” (3 versions), all of which you promote as products containing cannabidiol (CBD).1 We have also reviewed your social media websites at www.facebook.com/CuraleafHemp External Link Disclaimer and https://twitter.com/curaleafhemp External Link Disclaimer; these websites direct consumers to your website, https://curaleafhemp.comExternal Link Disclaimer, to purchase your products. FDA has determined that your “CBD Lotion,” “CBD Pain-Relief Patch,” “CBD Tincture,” and “CBD Disposable Vape Pen” products are unapproved new drugs sold in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (the FD&C Act), 21 U.S.C. 355(a) and 331(d). Furthermore, these products are misbranded drugs under section 502(f)(1) of the FD&C Act, 21 U.S.C. 352(f)(1). FDA has also determined that your “Bido CBD for Pets” products are unapproved new animal drugs that are unsafe under section 512(a) of the FD&C Act, 21 U.S.C. 360b(a), and adulterated under section 501(a)(5) of the FD&C Act, 21 U.S.C. 351(a)(5). As explained further below, introducing or delivering these products for introduction into interstate commerce for such uses violates the FD&C Act. You can find the FD&C Act and FDA regulations through links on FDA’s home page at www.fda.gov.
Unapproved New and Misbranded Human Drug Products
Based on our review of your website, your “CBD Lotion,” “CBD Pain-Relief Patch,” “CBD Tincture,” and “CBD Disposable Vape Pen” products are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and/or intended to affect the structure or any function of the body.
Examples of claims observed on your website and social media accounts in April 2019 that establish the intended use of your products as drugs include, but may not be limited to, the following:
On your product webpage for CBD Disposable Vape Pen (Relieve):
• “[F]or chronic pain.”
On your product webpage for CBD Tincture (Relieve):
• “[S]oothing tincture for chronic pain.” …..
- Details
- Hits: 1764
C.A.L.M (Californians Against Legalizing Marijuana) Interview: Californian Cannabis Chaos – Broken Promises, Broken Budget, Broken Community!
http://ftpcontent.worldnow.com/kfmbam/podcast/audio/mark_larson_27080.mp3